Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the webspellchecker domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/gulfindex35/public_html/ijphs.org/wp-includes/functions.php on line 6131
Drug Review: Eplontersen – IJPCS

Drug Review: Eplontersen

International Journal of Pharmacology and Clinical Sciences, 2024, 13, 1, 10.
Published: November 2024
Type: Drug Review
Authors: Juman Alsaab
 
Author(s) affiliations:

Juman Alsaab,

Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA.

Abstract

Regulations: had been registered in the following countries: UnitedStates of America (USA). Registration number (S.A.): Not available. Insurance Drug Formulary (S.A.): Not available. General Information: Registered Company: Ionis Pharmaceuticals and AstraZeneca. Regulatory Status: R.X.Mechanism of Action: Plontersen, an antisense oligonucleotideGa1NAc conjugate, is structurally represented as [insert chemical structure here]. This drug causes degradation of mutant and wild-type transthyretin (TTR) mRNA through binding to the TTR mRNA. Read more…



Leave a Reply

Your email address will not be published. Required fields are marked *